Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 5/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089057 | 0.89 | KDR (0.37) | CRBNBRD4LMNAL3MBTL1KDR | |
| SCHEMBL23674977 | 0.87 | CRBN (0.35) | CRBNBRD4LMNAL3MBTL1KDR | |
| SCHEMBL21646064 | 0.82 | MAP4K1 (0.51) | CRBNMAP4K1 | |
| SCHEMBL31329495 | 0.82 | MAP4K1 (0.51) | CRBNMAP4K1 | |
| SCHEMBL31329494 | 0.82 | MAP4K1 (0.51) | CRBNMAP4K1 | |
| SCHEMBL26441299 | 0.81 | BRD4 (0.57) | CRBNBRD4ALK | |
| SCHEMBL30100769 | 0.81 | BRD4 (0.57) | CRBNBRD4ALK | |
| SCHEMBL30100774 | 0.80 | BRD4 (0.39) | CRBNBRD4LMNAL3MBTL1KDR | |
| SCHEMBL26086551 | 0.80 | BRD4 (0.39) | CRBNBRD4LMNAL3MBTL1KDR | |
| SCHEMBL21687088 | 0.80 | CRBN (0.40) | CRBNLMNAL3MBTL1KDRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | OTUD7B 3029/4885CRBN 3317/4885BRD4 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.